Off-target autophagy inhibition by SHP2 allosteric inhibitors contributes to their antitumor activity in RAS-driven cancers

Aberrant activation of RAS/MAPK signaling is common in cancer, and efforts to inhibit pathway components have yielded drugs with promising clinical activities. Unfortunately, treatment-provoked adaptive resistance mechanisms inevitably develop, limiting their therapeutic potential. As a central node...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yiming Miao, Yunpeng Bai, Jinmin Miao, Allison A. Murray, Jianping Lin, Jiajun Dong, Zihan Qu, Ruo-Yu Zhang, Quyen D. Nguyen, Shaomeng Wang, Jingmei Yu, Frederick Nguele Meke, Zhong-Yin Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Clinical Investigation 2024-08-01
coleção:	The Journal of Clinical Investigation
Assuntos:	Oncology Therapeutics
Acesso em linha:	https://doi.org/10.1172/JCI177142
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!